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Background: Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a major cause of liver-related morbidity 
and mortality. The underlying mechanisms of disease progression remain poorly understood, and primary therapy of NAFLD is 
not yet established. We investigated the effects of dietary oleate on the development and progression of NAFLD in a methionine- 
and choline-deficient (MCD) diet-fed animal model. 
Methods: A total of 30 C57BL/6J mice were randomly divided into three groups (n=10 in each group) and fed various experi-
mental diets for four weeks: chow, MCD diet, or OMCD (MCD diet with oleate, 0.5 mg/g/day). Liver samples were examined for 
steatohepatitis and fibrosis parameters and associated genes. 
Results: Additional dietary oleate dramatically reduced MCD diet-induced hepatic steatosis. Hepatic carbohydrate responsive 
element-binding protein was overexpressed in MCD diet-fed mice, and dietary oleate prevented this overexpression (P<0.001). 
Dietary oleate partially prevented MCD diet-induced serum level increases in aspartate aminotransferase and alanine aminotrans-
ferase (P<0.001, respectively). The mRNA expressions of hepatic monocyte chemoattractant protein 1, tumor necrosis factor-α 
and matrix metalloproteinase-9 were increased in MCD diet-fed mice, and this overexpression of inflammatory molecules was 
prevented by dietary oleate (P<0.001). Hepatic pericellular fibrosis was observed in MCD diet-fed mice, and dietary oleate pre-
vented this fibrosis. Altogether, dietary oleate prevented MCD diet-induced hepatic steatosis, inflammation and fibrosis. 
Conclusion: Dietary oleate has beneficial effects in every step of NAFLD development and progression and could be a nutri-
tional option for NAFLD prevention and treatment.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) represents a spec-
trum of disorders characterized by hepatic fat accumulation 
ranging from simple steatosis to severe non-alcoholic steato-
hepatitis (NASH) with centrilobular necroinflammation and 
has been increasingly recognized as a major cause of liver-re-
lated morbidity and mortality [1]. Although the underlying 
mechanisms of disease progression remain poorly understood, 
insulin resistance, oxidative stress, and an inflammatory cas-
cade are believed to play important roles in the development 
and progression of this disease [1-3]. The treatment of NAFLD 
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consists of modification of underlying risk factors and detec-
tion of patients with liver cirrhosis. Although some agents 
provide modest improvements in liver function tests and his-
tologic parameters, primary therapy for NAFLD has not yet 
been established [2].
 The methionine- and choline-deficient (MCD) diet is a well-
established and widely-used nutritional model of human 
NAFLD. This high sucrose-containing diet lacks methionine 
and choline in its composition, contains a higher lipid compo-
sition than a normal chow diet, and causes hepatic steatosis 
and inflammation that mimics NAFLD in humans [4,5]. Al-
though the mechanisms responsible for the development of 
hepatic steatosis due to the MCD diet are not fully understood, 
recent studies suggest that the MCD diet increases hepatic fat-
ty acid uptake and decreases very low-density lipoprotein 
(VLDL) secretion [4].
 Oleic acid (18:1n-9), the richest source of fatty acid in olive 
oil, is a monounsaturated fatty acid (MUFA). Recently, dietary 
olive oil was reported to decrease hepatic lipid content in rats 
fed an MCD diet [6]. Considering that only 15% of fatty acid 
stored in the liver is of dietary origin in NAFLD patients [7], 
reduced plasma free fatty acid (FFA) and de novo lipogenesis 
were suggested as possible mechanisms to prevent the accu-
mulation of fatty acids in the liver under an olive oil-enriched 
diet [6]. In fact, MUFA from safflower oil was reported to de-
crease lipogenesis in the rat liver [8]. Additionally, recent stud-
ies show that a diet rich in olive oil decreases hepatic injury 
and apoptosis in mice fed an MCD diet [9]. However, to our 
knowledge, there are few studies that have investigated the ef-
fect of dietary MUFA on each stage of NAFLD development 
and progression.
 In this study, we investigated the effect of dietary oleate on 
the development and progression of NAFLD in a MCD-diet 
mouse model. This study presents some clues to understand-
ing the mechanisms through which the MCD diet induces ste-
atohepatitis and describes how dietary MUFA prevents steato-
hepatitis in this animal model. As a result, this study suggests 
dietary oleate as a nutritional option for NAFLD prevention 
and treatment.
METHODS
Animals, diet, and treatment
Eight-week-old C57BL/6J mice (Samtako Inc., Osan, Korea) 
weighing 20 to 21 g were maintained at ambient temperature 
(22±1°C) on 12-hour light-dark cycles with free access to wa-
ter and diet. Initially, all mice were fed a chow diet during a 
one-week quarantine and acclimation period. Then, at nine 
weeks of age, mice displaying no abnormal findings at the end 
of the quarantine and acclimation period were randomly di-
vided into three groups. The mice in the chow group (n=10) 
were fed a normal chow diet; the mice in the MCD group (n=
10) were fed an MCD diet (Dyets Inc., Bethlehem, PA, USA); 
the mice in the OMCD group (n=10) were fed an MCD diet 
with oleate supplementation (0.5 mg/g/day; Sigma Aldrich, St. 
Louis, MO, USA) throughout the four weeks of the experi-
mental period. Oleate was orally administrated with a 10 cc 
syringe, and body weights were measured every other day. 
Mice were sacrificed at 13 weeks of age. The animals were eu-
thanized at the end of a dark cycle after overnight fasting for 
tissue sampling. Blood was collected by cardiac puncture, and 
the livers were isolated, immediately freeze-clamped in liquid 
nitrogen, and stored at -80°C until analysis. All experimental 
procedures were performed under sterile conditions and were 
approved by the Institutional Animal Care and Use Commit-
tee at Yonsei University College of Medicine.
Biochemical examination
Plasma levels of aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were assayed by routine automated 
laboratory methods.
Histopathological analysis
Livers were weighed to allow the calculation of relative liver 
weight (percentage of liver weight to body weight). Livers were 
fixed in 10% buffered formalin, embedded in paraffin, and 
sectioned at 3 μm. Standard hematoxylin and osin (H&E) and 
trichrome staining was performed [10]. Fresh tissue was fro-
zen immediately after each animal was dissected, and the tis-
sue was placed in pre-labeled base molds filled with embed-
ding medium used for frozen tissue to ensure the optimal cut-
ting temperature (OCT). Routine sections were cut at 7 μm, 
frozen and stained with Oil-red O. For the evaluation of he-
patic steatosis and fibrosis, the average areas (%) of the fat 
droplets and fibrosis within hepatocytes were measured with 
the aid of an image analyzer in three randomly selected fields 
(magnification, ×100) of each section stained with Oil-red O 
and trichrome [11].
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Immunohistochemistry
Immunohistochemistry was performed with an antibody to 
carbohydrate responsive element-binding protein (ChREBP) 
(Thermo Fisher Scientific Inc., Rockford, IL, USA) on paraf-
fin-embedded sections. Immunohistochemical staining was 
performed with an ABC staining system (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) [12].
RNA and cDNA preparation
Total RNA was isolated from mouse liver tissue using Trizol 
reagent (Invitrogen, Carlsbad, CA, USA) and quantified using 
a Nano Drop instrument (ND-1000; DM Science, Seoul, Ko-
rea). Following RNA extraction, 4 μL RNA was treated with 1 
U DNase I to remove all contaminating genomic DNA. DN-
ase-treated RNA was subsequently used for cDNA synthesis 
using MMLV reverse transcriptase (Promega, Madison, WI, 
USA): 1 μL oligo dT primer was added to 4 μL RNA in 5× 
MMLV reaction buffer, 2.5 mM each dNTP, 1 U RNasin ribo-
nuclease inhibitor and MMLV reverse transcriptase (200 units). 
cDNA was stored at -20°C.
Quantitative RT-PCR
Real-time quantitative reverse transcription-polymerase chain 
reaction (RT-PCR) analysis was performed with an ABI 7500 
instrument and software (Applied Biosystems, Foster City, CA, 
USA). PCR reactions were performed in triplicate in a final 
volume of 20 μL according to the manufacturer’s protocol. 
Mouse ChREBP mRNA expression was analyzed using Taq-
man probes (Mm02342723_m1; Applied Biosystems). For 
each assay, a standard curve was obtained by analyzing a dilu-
tion series of pooled cDNA samples for the relevant gene. Data 
were analyzed with Sequence Detector 1.7 software (Applied 
Biosystems). Mouse glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was used as the internal standard to control 
for variability, and results were expressed as a ratio of the gene 
expression relative to that of GAPDH.
Semi-quantitative RT-PCR
The hepatic expressions of the mRNAs for apolipoprotein B100 
(APOB100), monocyte chemoattractant protein 1 (MCP1), tu-
mor necrosis factor-α (TNF-α) and matrix metalloprotein-
ase-9 (MMP-9) were assessed by semi-quantitative RT-PCR 
analysis using GAPDH as an internal control gene. RT-PCR 
products were electrophoresed on a 1% (w/v) agarose gel, the 
gel was stained with ethidium bromide, and bands were visu-
alized by UV light. The primers used for RT-PCR are listed in 
Table 1. Samples from all experimental animals were used for 
this analysis.
Statistical analysis
All statistical analyses were performed with SPSS software ver-
sion 15.0 (SPSS Inc., Chicago, IL, USA). Values were expressed 
as mean±standard deviation. Statistical analyses were per-
formed using the unpaired Student’s t-test or one-way ANO-
VA. Data with a P value less than 0.05 were considered statisti-
cally significant.
RESULTS
An MCD diet decreased body weight and relative liver 
weight
After the four week-experimental period, the body weights of 
the MCD diet-fed mice significantly decreased compared to 
those of the chow diet-fed mice (chow vs. MCD vs. OMCD, 
25.0±0.7 g vs. 15.3±0.8 g vs. 15.6±1.2 g, P<0.001) (Table 2). 
Relative liver weights in the MCD diet-fed groups were signifi-
cantly increased compared to those in the chow diet-fed 
group. Between the MCD diet-fed groups, the increase in rela-
tive liver weight in mice fed an MCD diet only was more prom-
inent than that in mice fed an MCD diet with oleate (chow vs. 
MCD vs. OMCD, 4.8±0.5% vs. 6.5±0.4% vs. 5.8±0.6%, P<
0.001) (Table 2).
Dietary oleate prevented steatosis in the liver of mice fed 
an MCD diet
To investigate and compare the extent of hepatic steatosis 
among the groups, Oil-Red-O staining of mice liver samples 
was performed. In the MCD diet-fed mice, numerous fat 
Table 1. RT-PCR primers
Gene Forward primer (5′ to 3′) Reverse primer (3′ to 5′) 
APOB100 cgtctcctcagccaaaacaa caggtgacggtctgacttgg
MCP1 tggatcggaaccaaatgaga aggcatcacagtccgagtca
TNF-α agcacagaaagcatgatccg tttgctacgacgtgggctac
MMP-9 cctgcagtgcccttgaacta ttgtcttcttgctcggatgc
GAPDH ggagccaaaagggtcatcat gtgatggcatggactgtggt
RT-PCR, reverse transcription-polymerase chain reaction; APOB100, 
apolipoprotein B100; MCP1, monocyte chemoattractant protein 1; 
TNF-α, tumor necrosis factor-α; MMP-9, matrix metalloproteinase-9; 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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significantly decreased compared to those of the MCD diet-
fed mice (MCD vs. OMCD, 14.31±0.35% vs. 3.65±0.04%, 
P<0.001) (Fig. 1). 
Hepatic ChREBP overexpression and APOB100 reduction 
by an MCD diet are inhibited by dietary oleate
To investigate the effect of dietary MUFA on hepatic de novo 
lipogenesis, ChREBP expression in each group was evaluated. 
Immunohistochemical staining revealed that hepatic ChREBP 
was overexpressed in mice fed an MCD diet compared to that 
of chow diet-fed mice (Fig. 2A and B). Interestingly, dietary 
oleate completely attenuated MCD diet-induced overexpres-
Table 2. Clinical characteristics of mice after four weeks of 
experimental diets
Characteristic
Dietary group
Chow MCD OMCD
Initial body weight, g 21.8±0.5 21.8±1.4 22.1±1.4
Body weight, g 25.0±0.7 15.3±0.8a 15.6±1.2b
Liver weight, g 1.2±0.2 0.9±0.1a 1.0±0.1b,c
Liver weight-body 
weight, %
4.8±0.5 6.5±0.4a 5.8±0.6b,c
Serum AST, IU/L 85.3±5.9 465.5±6.8a 356.5±6.4b,c
Serum ALT, IU/L 38.7±9.7 658.3±8.4a 450.2±7.2b,c
Values represent mean±standard deviation for n=10 in each group.
Chow, normal chow diet; MCD, methionine- and choline-deficient 
diet; OMCD, MCD diet with oleate (0.5 mg/g/day); AST, aspartate 
aminotransferase; ALT, alanine aminotransferase. 
aP<0.05 for MCDD vs. chow, bP<0.05 for OMCDD vs. chow, cP<0.05 
for OMCD vs. MCD.
A
C
B
D
Fig. 1. The effects of the methionine- and choline-deficient 
diet (MCD) diet and dietary oleate on hepatic fat accumula-
tion. Oil-red-O staining of frozen liver sections. Scale bars, 
200 μm. (A) Chow diet-fed mice. (B) MCD diet-fed mice. (C) 
MCD diet with oleate (0.5 mg/g/day for 4 weeks)-fed mice. 
(D) The areas of fat droplets, measured by image analyzer in 
three randomly selected fields (magnification, ×100) of each 
liver section. Chow, normal chow diet; OMCD, MCD diet 
with oleate. aP<0.05 vs. chow, bP<vs. MCD.
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droplets were observed within hepatocytes, and the total fat 
droplet area was markedly increased in the livers of MCD di-
et-fed mice (chow vs. MCD, 0.05±0.01% vs. 14.31±0.35%, 
P<0.001) (Fig. 1). This increase in hepatic lipid droplets in 
mice fed an MCD diet was attenuated by dietary oleate. In the 
livers of oleate-treated MCD diet-fed mice, lipid droplets were 
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Fig. 2. The effects of the methionine- and choline-deficient 
diet (MCD) diet and dietary oleate on hepatic carbohydrate 
responsive element-binding protein (ChREBP) and apolipo-
protein B (apo B) expression. Immunohistochemical detection 
of ChREBP in liver paraffin-embedded sections. Scale bars, 50 
μm. (A) Chow diet-fed mice. (B) MCD diet-fed mice. (C) MCD 
diet with oleate (0.5 mg/g/day for 4 weeks)-fed mice. (D) Real-
time reverse transcription-polymerase chain reaction (RT-PCR) 
quantification of ChREBP mRNA in mouse liver samples from 
each group. (E) Real-time RT-PCR quantification of APOB100 
mRNA in mouse liver samples from each group. AU, arbitrary 
unit; Chow, normal chow diet; OMCD, MCD diet with oleate. 
aP<0.05 vs. chow, bP<vs. MCD.
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sion of hepatic ChREBP (Fig. 2C). The results of quantitative 
RT-PCR demonstrate that the mRNA expression of hepatic 
ChREBP was markedly increased by the MCD diet, and oleate 
intake prevented this increase (chow vs. MCD vs. OMCD, 
1.00±0.07 AU vs. 1.90±0.14 AU vs. 1.10±0.07 AU, P<0.001) 
(Fig. 2D).
 Hepatic APOB100 expression was evaluated to investigate 
the effect of dietary MUFA on hepatic VLDL excretion. The 
mRNA expression of hepatic APOB100 tended to be reduced 
in the MCD diet-fed mice, and dietary oleate prevented this 
reduction (chow vs. MCD vs. OMCD, 1.00±0.25 AU vs. 0.75± 
0.25 AU vs. 1.10±0.39 AU, P=0.065) (Fig. 2E). 
Dietary oleate prevented steatohepatitis and fibrosis in the 
livers of MCD diet-fed mice
To investigate the hepatic inflammatory status of each group, 
serum AST and ALT levels were measured. As expected, the 
MCD diet increased serum AST and ALT levels (AST, chow 
vs. MCD, 85.3±5.9 IU/L vs. 465.5±6.8 IU/L, P<0.001; ALT, 
chow vs. MCD, 38.7±9.7 IU/L vs. 658.3±8.4 IU/L, P<0.001) 
(Table 2). Oleate intake partially prevented these increases in 
serum AST and ALT levels (AST, MCD vs. OMCD, 465.5±6.8 
IU/L vs. 356.5±6.4 IU/L, P<0.001; ALT, MCD vs. OMCD, 
658.3±8.4 IU/L vs. 450.2±7.2 IU/L, P<0.001) (Table 2). H&E 
staining of mice liver samples displayed increased inflamma-
tory cells and focal aggregates of inflammatory cells in MCD 
Fig. 3. Liver histology in mice fed each experimental diet. 
H&E staining of liver paraffin-embedded sections. Scale bars, 
200 μm. (A) Chow diet-fed mice. (B) MCD diet-fed mice. (C) 
MCD diet with oleate (0.5 mg/g/day for 4 weeks)-fed mice. 
Arrows indicate the focal aggregation of inflammatory cells. 
Chow, normal chow diet; MCD, methionine- and choline-de-
ficient diet; OMCD, MCD diet with oleate.
A
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B
diet-fed mice compared to the responses in chow diet-fed or 
OMCD diet-fed mice (Fig. 3). The results of semi-quantitative 
RT-PCR demonstrate that the mRNA expressions of hepatic 
MCP1, TNF-α and MMP-9 were increased in the MCD diet-
fed mice, and this overexpression of inflammatory cytokines 
was prevented by dietary oleate (MCP1, chow vs. MCD vs. 
OMCD, 1.00±0.07 AU vs. 1.95±0.14 AU vs. 1.51±0.11 AU, 
P<0.001; TNF-α, 1.00±0.08 AU vs. 1.93±0.11 AU vs. 1.12±
0.11 AU, P<0.001; MMP-9, 1.00±0.07 AU vs. 1.83±0.11 AU 
vs. 1.24±0.12 AU, P<0.001) (Fig. 4).
 Trichrome staining of mice liver samples was used to evalu-
ate the hepatic pericellular fibrosis in each group. Pericellular 
fibrosis and numerous collagen fibers were observed in livers 
from the MCD diet-fed mice, but the number of liver collagen 
fibers was not higher than that of chow diet-fed mice in oleate-
Fig. 4. The effects of the methionine- and choline-deficient 
diet (MCD) diet and dietary oleate on hepatic inflammatory 
molecules. Semi-quantitative reverse transcription-polymerase 
chain reaction (RT-PCR) for inflammatory molecules in mouse 
liver samples from each group. (A) MCP1. (B) TNF-α. (C) 
MMP-9. MCP1, monocyte chemotactic protein 1; TNF-α, tu-
mor necrosis factor-α; MMP-9, matrix metalloproteinase-9; 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; AU, ar-
bitrary unit; Chow, normal chow diet; MCD, methionine- and 
choline-deficient diet; OMCD, MCD diet with oleate (0.5 mg/
g/day for 4 weeks). aP<0.05 vs. chow, bP<vs. MCD.
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treated mice (relative fibrosis area, chow vs. MCD vs. OMCD, 
1.00±0.05 AU vs. 1.96±0.06 AU vs. 1.10±0.05 AU, P<0.001) 
(Fig. 5).
DISCUSSION
This study demonstrated that dietary oleate prevented MCD 
diet-induced steatohepatitis and hepatic fibrosis via an in-
crease in hepatic triglyceride excretion and decreases in he-
patic de novo lipogenesis and inflammation. The MCD diet is 
a well-established and widely-used nutritional model of ste-
atohepatitis thatcauses hepatic steatosis and inflammation that 
mimics NAFLD in humans [4,5]. In this study, as expected, 
hepatic steatosis developed in the MCD diet-fed mice. Addi-
tionally, the MCD diet tended to reduce hepatic APOB100. 
This result suggests a decrease in hepatic VLDL excretion and 
is consistent with previous studies [4,13]. Surprisingly, our re-
sults showed that the MCD diet induced an important lipo-
genic transcription factor in the liver, ChREBP. ChREBP regu-
lates hepatic de novo lipogenesis in response to elevated glucose 
concentrations by binding lipogenic enzyme genes [14,15]. Pre-
vious studies reported the opposite results for another lipo-
genic transcription factor, sterol regulatory element-binding 
protein-1 (SREBP-1) [4,16,17]. In those studies, reduced mRNA 
expression or nuclear levels of hepatic SREBP-1 were observed 
in the MCD diet-fed mice compared with those in the chow 
diet-fed mice, but no consistent reduction in fatty acid synthe-
sis genes, such as acetyl-CoA carboxylase (ACC) and fatty acid 
synthase (FAS), was noted [16,17]. Our results might explain 
this discrepancy; ACC and FAS are regulated not only by 
SREBP-1 but also by ChREBP; thus, the overexpression of 
ChREBP due to an MCD diet might maintain the expression 
of fatty acid synthesis genes. In fact, hepatic de novo lipogene-
sis is not known to contribute to the development of hepatic 
steatosis in the MCD diet animal model [4,13,16,17]. Al-
though the MCD diet induced hepatic ChREBP overexpres-
sion in our study, this result does not mean that hepatic steato-
sis is due to increased hepatic lipogenesis because MCD diet-
induced hepatic ChREBP overexpression could be a compen-
satory response for decreased hepatic de novo lipogenesis. 
Furthermore, we did not investigate downstream lipogenic 
regulation of ChREBP. Nevertheless, considering glucose-in-
duced ChREBP activation and the up-regulation of ChREBP 
in a diabetic condition, the steatogenetic potential of this over-
expression of hepatic ChREBP by an MCD diet might be mag-
nified in the condition of hyperglycemia, even if the increase 
in hepatic de novo lipogenesis is not a main mechanism of 
MCD diet-induced hepatic steatosis. Actually, in Otsuka Long-
Evans Tokushima Fatty rats, an animal model of type 2 diabe-
tes with insulin resistance and hyperglycemia, it was reported 
that the development of hepatic fat accumulation, inflamma-
tion and fibrosis due to an MCD diet was accelerated com-
pared with that in non-diabetic control rats [18]. In a report 
with db/db mice, another diabetic animal model, hepatic fi-
brosis induced by an MCD diet was more prominent than that 
in non-diabetic db/m mice [19].
 Previous studies have reported the effect of dietary MUFA 
against steatohepatitis in NAFLD animal models. A study with 
rats fed an MCD diet show that the extent of hepatic fatty infil-
tration and hepatic triglyceride content were lower in the rats 
fed an MCD diet with olive oil (0.45 mg/g rat weight) than in 
the rats fed an MCD diet only [6]. The authors of that study 
suggested MUFA from olive oil might inhibit hepatic triglyc-
eride synthesis on the basis of prior studies reporting reduced 
lipogenesis in the rat liver due to dietary MUFA from safflow-
er oil [6,8]. In the present study, hepatic steatosis was reduced 
in mice fed an MCD diet with oleate compared with that in 
A
C
B
Fig. 5. The effects of the methionine- and choline-deficient 
diet (MCD) diet and dietary oleate on hepatic fibrosis. Tri-
chrome staining of liver paraffin-embedded sections. Scale 
bars, 200 μm. (A) Chow diet-fed mice. (B) MCD diet-fed mice. 
(C) MCD diet with oleate (0.5 mg/g/day for 4 weeks)-fed mice. 
(D) The areas of fibrosis, measured by image analyzer in three 
randomly selected fields (magnification, ×100) of each liver 
section. AU, arbitrary unit; Chow, normal chow diet; OMCD, 
MCD diet with oleate. aP<0.05 vs. chow, bP<vs. MCD.
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the mice fed an MCD diet only. Additionally, dietary oleate al-
most completely prevented the decrease in hepatic APOB100 
expression, and the MCD diet induced overexpression of he-
patic ChREBP in mice. These results suggest that dietary ole-
ate prevents hepatic steatosis by maintaining hepatic VLDL 
excretion, as well as by reducing hepatic de novo lipogenesis in 
this animal model. As mentioned above, increased hepatic 
ChREBP does not mean that hepatic de novo lipogenesis con-
tributes to the development of steatohepatitis in this animal 
model. However, we can suggest that dietary oleate prevented 
MCD diet-induced hepatic steatosis, and this effect, at least in 
part, is associated with the reduced expression of hepatic 
ChREBP and suppression of hepatic de novo lipogenesis. In 
addition, our results also suggest that dietary oleate might be 
more effective against hepatic steatosis in a hyperglycemic or 
insulin-resistant status.
 In the present study, we cannot confirm whether the change 
in hepatic ChREBP expression is a direct effect of the MCD 
diet or dietary oleate. Although it has been reported that poly-
unsaturated fatty acids (PUFA) suppress ChREBP activity in 
primary hepatocytes by increasing ChREBP mRNA decay 
[20], and high glucose concentration down-regulates the ex-
pression of ChREBP mRNA in insulinoma cells [21], the regu-
lation of ChREBP mRNA transcription or translation is not 
well understood [14]. The mechanisms through which the 
MCD diet increases hepatic ChREBP expression and dietary 
oleate prevents this overexpression need to be further investi-
gated. 
 H&E staining of the liver showed increased and focally ag-
gregated inflammatory cells in the livers of MCD diet-fed mice. 
Dietary oleate prevented this aggregation of hepatic inflam-
matory cells. These results are consistent with our results of 
increased MCP1 mRNA expression in the liver of MCD diet-
fed mice and reduced expression by dietary oleate. MCP-1 is a 
potent chemotactic factor for monocytes and is derived pre-
dominantly from macrophages and endothelial cells [22,23]. 
The MCD diet and dietary oleate also affected the expressions 
of other hepatic inflammatory molecules, such as TNF-α and 
MMP-9. Biologically, TNF-α activates a cascade of cytokine 
production [24], and MMP-9 plays a crucial role for the mi-
gration, extravasation, and infiltration of immune cells, in-
cluding monocytes [25]. TNF-α, in particular, is implicated in 
the pathogenesis of NAFLD [2]. Elevated levels of TNF-α have 
been detected in obese patients with insulin resistance and 
also in patients with NASH [2]. In our results, the MCD diet 
induced TNF-α and MMP-9 mRNA expressions in the liver, 
and dietary oleate prevented the up-regulation of these in-
flammatory molecules. To our knowledge, this is the first study 
to report the effects of dietary MUFA on hepatic inflammato-
ry molecules in a NAFLD animal model.
 To explain the pathogenesis of NAFLD, a ‘‘multi-hit’’ (for-
merly ‘‘double-hit’’) hypothesis has been widely accepted; in-
sulin resistance and hepatic steatosis - the first hit - and subse-
quent development of inflammation or fibrosis - the second 
hit [2]. With trichrome staining, it was demonstrated that di-
etary oleate prevented MCD diet-induced hepatic fibrosis. This 
result suggests that dietary MUFA might prevent the develop-
ment of cirrhosis resulting from NAFLD. Further, considering 
the “multi-hit hypothesis,” our results showing the effects of 
dietary oleate on hepatic steatosis, inflammation and fibrosis 
suggest that dietary MUFA has beneficial effects in every step 
of NAFLD development and progression.
 In conclusion, our data suggest that dietary MUFA can pre-
vent hepatic steatosis by reducing hepatic ChREBP overex-
pression, as well as by inducing APOB100 expression. Addi-
tionally, our data suggest that dietary MUFA inhibits the de-
velopment of hepatic inflammation and fibrosis by suppress-
ing several inflammatory molecules. Altogether, dietary oleate 
has beneficial effects in every step of the development and 
progression of NAFLD and may be a nutritional option for 
NAFLD prevention and treatment. 
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